In Vitro Diagnostics Market Summary

The global in vitro diagnostics market was valued at USD 108.30 billion in 2024 and is anticipated to reach USD 150.13 billion by 2030, progressing at a CAGR of 5.62% from 2025 to 2030. This steady expansion reflects the growing worldwide need for diagnostic solutions that are accurate, rapid, and increasingly personalized.

Rising incidence of chronic and infectious diseases, continuous technological breakthroughs, and a healthcare shift toward early detection and preventive care are central forces behind this growth. The integration of digital health platforms, artificial intelligence, and advanced analytics into diagnostic workflows is enhancing precision, efficiency, and clinical decision-making. Simultaneously, expansion of point-of-care (POC) testing, personalized medicine initiatives, emerging economies, and heightened global pandemic preparedness are strengthening adoption across healthcare systems.

A significant driver remains the growing burden of chronic illnesses and genetic disorders such as Alzheimer’s disease, Turner syndrome, and Parkinson’s disease. According to the CDC, chronic diseases—including cancer, diabetes, kidney disorders, and respiratory conditions like asthma—account for 7 in 10 deaths in the U.S. each year, with 6 out of 10 adults living with at least one chronic disease. These conditions generate approximately USD 4.1 trillion in annual healthcare costs in the U.S. alone.

In 2024, 620,000 cases and 213 deaths were detected globally in a notable infectious disease outbreak, primarily across the Americas, with Brazil, Paraguay, and Argentina reporting the highest burden. Asia recorded significant cases in India and Pakistan, while Senegal was the only affected African country. Europe reported one locally acquired case in France and 118 cases in La Réunion. Such developments underscore the urgent need for scalable, reliable diagnostic platforms.

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

Technological evolution continues to redefine diagnostic capabilities. Innovations in miniaturization, nanotechnology, microfluidics, and cloud-connected POC systems are making molecular diagnostics more accessible and affordable. Smartphone-integrated biosensors now allow real-time, on-site analysis, while 3D printing improves fabrication and efficiency of portable diagnostic devices. Flexible wireless sensors further enable remote monitoring for preventive healthcare and rapid outbreak detection. These advancements collectively signal a transformative era for molecular-level diagnostics worldwide.

Key Market Trends & Insights

• North America dominated the in vitro diagnostics industry with a 47.43% share in 2024.
• Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 6.57% during the forecast period.
• By product, the reagents segment captured 65.54% share in 2024.
• By technology, the immunoassay segment accounted for the largest revenue share in 2024.
• By application, the infectious diseases segment led the industry in 2024.

Market Size & Forecast

• 2024 Market Size: USD 108.30 Billion
• 2030 Projected Market Size: USD 150.13 Billion
• CAGR (2025–2030): 5.62%
• Largest Region (2024): North America
• Fastest Growing Region: Asia Pacific

Key In Vitro Diagnostics Company Insights

Leading organizations are strengthening their technological foundations and expanding global reach through innovation, partnerships, and acquisitions. Prominent companies shaping this space include:

• Abbott Laboratories
• bioMérieux
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.

These mature players invest heavily in advanced infrastructure, enabling large-scale data processing and high-throughput testing capabilities. Strategic moves such as product launches, mergers, collaborations, and geographic expansion continue to reinforce their leadership.

Emerging participants are also gaining traction by focusing on product differentiation and innovation. Companies such as ARUP Laboratories, RayBiotech, Inc., Randox Laboratories Ltd., Everlywell, Orreco, and Biostarks are actively introducing novel testing solutions. These organizations collaborate with research institutes, government agencies, and global partners to expand their footprint and deliver advanced diagnostic technologies to underserved markets.

Key In Vitro Diagnostics Companies

The following companies collectively command significant share and influence innovation trajectories:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• bioMérieux
• Becton, Dickinson and Company
• QIAGEN N.V.
• QuidelOrtho Corporation
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.

Explore Horizon Databook - The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The In Vitro Diagnostics Market is on a resilient growth trajectory, rising from USD 108.30 billion in 2024 to USD 150.13 billion by 2030, fueled by a 5.62% CAGR. Escalating chronic disease prevalence, technological innovation, digital integration, and global preparedness for infectious threats are redefining diagnostic frameworks worldwide.

As healthcare systems transition toward precision medicine and preventive strategies, in vitro diagnostics will remain central to timely disease detection, improved patient outcomes, and cost-effective healthcare delivery. With continued innovation in molecular testing, AI-powered analytics, and portable POC platforms, the sector is positioned to become an even more critical pillar of global healthcare infrastructure.